Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 2/1999

01-06-1999 | SHORT COMMUNICATION

Distribution of daunorubicin and daunorubicinol in human glioma tumors after administration of liposomal daunorubicin

Authors: Massimo Zucchetti, Amerigo Boiardi, Antonio Silvani, Idria Parisi, Stefano Piccolrovazzi, Maurizio D'Incalci

Published in: Cancer Chemotherapy and Pharmacology | Issue 2/1999

Login to get access
Metadata
Title
Distribution of daunorubicin and daunorubicinol in human glioma tumors after administration of liposomal daunorubicin
Authors
Massimo Zucchetti
Amerigo Boiardi
Antonio Silvani
Idria Parisi
Stefano Piccolrovazzi
Maurizio D'Incalci
Publication date
01-06-1999
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 2/1999
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s002800050964

Other articles of this Issue 2/1999

Cancer Chemotherapy and Pharmacology 2/1999 Go to the issue

ORIGINAL ARTICLE

Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer

ORIGINAL ARTICLE

Biomodulation of 5-fluorouracil by interferon-α in human renal carcinoma cells: relationship to the expression of thymidine phosphorylase

SHORT COMMUNICATION

Reversible nephrotoxicity of onconase and effect of lysine pH on renal onconase uptake

ORIGINAL ARTICLE

Phase II studies with DaunoXome in patients with nonresectable hepatocellular carcinoma: clinical and pharmacokinetic outcomes

ORIGINAL ARTICLE

Supraadditive effect of 2′,2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines

ORIGINAL ARTICLE

Immunosuppressant inhibition of P-glycoprotein function is independent of drug-induced suppression of peptide-prolyl isomerase and calcineurin activity
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits